Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thomas Rogers

Physician Assistant, Surgical Sartell, MN Physician Assistant

NPI 1982234514 CMS profile 10806811

1901 Connecticut Ave S, Sartell, MN 56377

Open in the dashboard

General payments

$1,518

20 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Rogers of Sartell, MN is reported in the CMS Open Payments database as having received $1,518 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,243 11
2024 General $24 1
2023 General $98 4
2022 General $21 1
2021 General $132 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Rogers
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Thomas Rogers were reported at $1,243. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Thomas Rogers Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $132 $111 $36–$285 $132
2022 $21 $126 $44–$350 $149
2023 $98 $137 $47–$355 $160
2024 $24 $146 $49–$384 $164
2025 $1,243 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,243 11 payments
  2. Stryker Corporation $193 6 payments
  3. Bioventus LLC $38 1 payment
  4. Arthrex, Inc. $24 1 payment
  5. Ethicon US, LLC $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $897 3 payments
  2. Food and Beverage $621 17 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $1,243 11 payments
  2. MAKO $135 5 payments
  3. PRIME SERIES $58 1 payment
  4. Exogen Ultrasound Bone Healing System $38 1 payment
  5. STRATAFIX $21 1 payment
  6. SURGIFLO Hemostatic Matrix $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

516

Median for Physician Assistant: 241

Drug cost

$1,942

Median for Physician Assistant: $4,110

Branded share of claims

24.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 104 $710
Amoxicillin Generic 222 $346
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 22 $197
Oxycodone Hcl Generic 32 $194
Meloxicam Generic 29 $185
Gabapentin Generic 11 $84
Clindamycin Hcl Generic 46 $83
Cephalexin Generic 23 $63
Hydroxyzine Pamoate Generic 12 $61
Tramadol Hcl Generic 15 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$42,125

Of which drugs: $21,185

Medicare patients

184

Average age 74

Services billed

6,241

130 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 27%
Diabetes 24%
Chronic kidney disease 23%
Osteoporosis 18%
Ischemic heart disease 14%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 16 69 $6,308
Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg J7331 Office 15 680 $5,578
Injection, methylprednisolone acetate, 1 mg J1010 Office 60 3,561 $350

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record